Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo

• Main Authors: Nishioka, C, Ikezoe, T, Yang, J, Miwa, A, Tasaka, T, Kuwayama, Y, Togitani, K, Koeffler, H.P, Yokoyama, A
• Other Authors: DEPT OF MEDICINE
• Format: Article
• Published: American Society of Hematology 2020
• Subjects: antineoplastic agent; CD135 antigen; imatinib; ki 11502; mitogen activated protein kinase; protein bcl 2; protein kinase B; protein tyrosine kinase inhibitor; STAT5 protein; unclassified drug; Ki11502; protein kinase inhibitor; protein tyrosine kinase; quinoline derivative; acute granulocytic leukemia; adult; aged; animal experiment; animal model; antineoplastic activity; apoptosis; article; cancer inhibition; cell cycle arrest; cell proliferation; cell selection; cellular distribution; controlled study; down regulation; drug mechanism; female; gene mutation; human; human tissue; leukemia; leukemia cell; male; mouse; nonhuman; priority journal; signal transduction; animal; drug antagonism; drug effect; mouse mutant; pathology; treatment outcome; tumor cell line; xenograft; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia; Mice; Mice, SCID; Protein Kinase Inhibitors; Quinolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/183927
• Institution: National University of Singapore

10.1182/blood-2007-06-098079